TPX-0022

· Turning Point Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TPX-0022, covering 2025-10-01 to 2025-10-01. Get the full timeline:

Most recent: Clinical Trial Update: Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET [Phase 1]

See pricing